SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-162037"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-162037" > Effects of alirocum...

  • White, H.D.Green Lane Cardiovascular Services, Auckland City Hospital, 5 Park Road, Grafton, Auckland, 1142, New Zealand (författare)

Effects of alirocumab on types of myocardial infarction: Insights from the ODYSSEY OUTCOMES trial

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019-05-23
  • Oxford University Press,2019
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-162037
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-162037URI
  • https://doi.org/10.1093/eurheartj/ehz299DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-399019URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:142007168URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299
  • Aims The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (=1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gabriel, Steg Ph.FACT (French Alliance for Cardiovascular Trials), F-CRIN network, Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Université Paris-Diderot, Sorbonne Paris-Cité, INSERM U-1148, 46 rue Henri Huchard, Paris, 75018, France; National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, United Kingdom (författare)
  • Szarek, M.Department of Epidemiology and Biostatistics, SUNY Downstate Medical Center School of Public Health, 450 Clarkson Avenue, Brooklyn, NY 11203, United States (författare)
  • Bhatt, D.L.Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States (författare)
  • Bittner, V.A.Division of Cardiovascular Disease, University of Alabama at Birmingham, 701 19th Street South - LHRB 310, Birmingham, AL 35294, United States (författare)
  • Diaz, R.Estudios Cardiológicos Latinoamérica, Instituto Cardiovascular de Rosario, Paraguay 160, Rosario, Santa Fe, Argentina,Duke Clinical Research Institute, 200 Morris Street, Durham, NC 27710, United States (författare)
  • Edelberg, J.M.Sanofi, 55 Corporate Drive, Bridgewater, NJ 08807, United States (författare)
  • Erglis, A.Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, University of Latvia, Pilsonu Street 13, Riga, LV1002, Latvia (författare)
  • Goodman, S.G.Canadian VIGOUR Centre, 2-132 Li Ka Shing Centre for Health Research Innovation, University of Alberta, Edmonton, AB T6G 2E1, Canada; St. Michael’s Hospital, University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8, Canada,Division of Cardiology, University of Colorado School of Medicine, 1700 N. Wheeling Street, Aurora, CO 80045, United States (författare)
  • Hanotin, C.Sanofi, 54-56 Rue la Boétie, Paris, 75008, France (författare)
  • Harrington, R.A.Stanford Center for Clinical Research, Department of Medicine, 300 Pasteur Drive, S-102, Stanford, CA 94305, United States (författare)
  • Wouter, Jukema J.Department of Cardiology, Leiden University Medical Center, 2300 RC, Leiden, Netherlands (författare)
  • Lopes, R.D.Duke Clinical Research Institute, 200 Morris Street, Durham, NC 27710, United States (författare)
  • Mahaffey, K.W.Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Grant S-102, Stanford, CA 94305, United States (författare)
  • Moryusef, A.Sanofi, 55 Corporate Drive, Bridgewater, NJ 08807, United States,Department of Medicine III, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main, 60590, Germany (författare)
  • Pordy, R.Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, United States (författare)
  • Roe, M.T.Duke Clinical Research Institute, 200 Morris Street, Durham, NC 27710, United States (författare)
  • Sritara, P.Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Rama VI Road10400, Thailand (författare)
  • Tricoci, P.CSL Behring, 1100 N Miami Blvd Ste 613, Durham, NC 27703, United States (författare)
  • Zeiher, A.M.Department of Medicine III, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main, 60590, Germany (författare)
  • Schwartz, G.G.Division of Cardiology, University of Colorado School of Medicine, 1700 N. Wheeling Street, Aurora, CO 80045, United States (författare)
  • ODYSSEY, OUTCOMES Investigators (författare)
  • Olsson, Anders,1940-Linköpings universitet,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten,Region Östergötland, Endokrinmedicinska kliniken,ODYSSEY OUTCOMES Investigators(Swepub:liu)andol21 (bidragsgivare)
  • Hagström, EmilUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)emhag677 (författare)
  • Ball, Eric (författare)
  • Green Lane Cardiovascular Services, Auckland City Hospital, 5 Park Road, Grafton, Auckland, 1142, New ZealandFACT (French Alliance for Cardiovascular Trials), F-CRIN network, Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Université Paris-Diderot, Sorbonne Paris-Cité, INSERM U-1148, 46 rue Henri Huchard, Paris, 75018, France; National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, United Kingdom (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:European Heart Journal: Oxford University Press40:33, s. 2801-28090195-668X1522-9645

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy